We started in 2019 as a medical device company, founded by a surgical physician who went on to treat over 15,000 patients with hormone deficiencies and invented the Atrocar for surgical pellet-based testosterone delivery and sold that patent portfolio in Summer of 2026. 

 

Our next step in the journey is the VIT-200, long-acting Testosterone  Microspheres delivered via Subcutaneous Autoinjections. The potential for a new "Standard of Care" through the accelerated 505(b)(2) pathway.

 

Our vision is more consistent optimal delivery, at a lower dose, with less frequent treatment intervals.